表紙
企業レポート

PharmaPoint:てんかん−−現在・将来の市場参入企業

PharmaPoint: Epilepsy - Current and Future Players

発行 GlobalData 商品コード 263603
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
PharmaPoint:てんかん−−現在・将来の市場参入企業 PharmaPoint: Epilepsy - Current and Future Players
出版日: 2013年02月25日 ページ情報: 英文 58 Pages
概要

当レポートでは、世界のてんかん関連市場における既存企業および新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)、市場全体と各企業の将来展望などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • UCB
    • エーザイ
    • Pfizer
    • GlaxoSmithKline
    • Novartis
    • Abbott
    • 大日本住友製薬

第5章 付録

図表一覧

目次
Product Code: GDHC1005FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: Epilepsy - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Epilepsy Market. The report identifies and analyses the key companies shaping and driving the global Epilepsy market. The report provides insight into the competitive Epilepsy landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Epilepsy
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Epilepsy sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Epilepsy Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Epilepsy market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. UCB
    • 4.3.2. Eisai
    • 4.3.3. Pfizer
    • 4.3.4. GlaxoSmithKline
    • 4.3.5. Novartis
    • 4.3.6. Abbott
    • 4.3.7. Dainippon Sumitomo Pharma

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Prevalent Epilepsy Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class Based on MOA
    • 5.4.4. Launch Dates and Patent and Market Exclusivity Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
    • 5.4.8. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Primary Research - Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Authors
    • 5.7.2. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Contact Us
  • 5.10. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Epilepsy, 2012-2022
  • Table 2: Global Epilepsy Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the Epilepsy Market, 2012
  • Table 4: UCB's Epilepsy Portfolio Assessment, 2012
  • Table 5: UCB SWOT Analysis, 2012
  • Table 6: Eisai's Epilepsy Portfolio Assessment, 2012
  • Table 7: Eisai SWOT Analysis, 2012
  • Table 8: Pfizer's Epilepsy Portfolio Assessment, 2012
  • Table 9: Pfizer SWOT Analysis, 2012
  • Table 10: GlaxoSmithKline's Epilepsy Portfolio Assessment, 2012
  • Table 11: GlaxoSmithKline SWOT Analysis, 2012
  • Table 12: Novartis' Epilepsy Portfolio Assessment, 2012
  • Table 13: Novartis SWOT Analysis, 2012
  • Table 14: Abbott's Epilepsy Portfolio Assessment, 2012
  • Table 15: Abbott SWOT Analysis, 2012
  • Table 16: Dainippon Sumitomo's Epilepsy Portfolio Assessment, 2012
  • Table 17: Dainippon Sumitomo SWOT Analysis, 2012
  • Table 18: Key Launch Dates
  • Table 19: Key Patent Expiries and Market Exclusivity Expiries*
  • Table 20: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Epilepsy by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Epilepsy, 2012-2022
Back to Top